Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1
Status:
Active, not recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the hypothesis that combined angiotensin receptor
blockade (ARB)/neprilysin (NEP) inhibition potentiates the effects of exogenous bradykinin,
substance P, and brain natriuretic peptide (BNP) on forearm blood flow or endothelial
tissue-type plasminogen activator (t-PA) release compared to ARB alone. A secondary goal is
to determine if there is an interactive effect of ARB/NEP inhibition and dipeptidyl peptidase
4 (DPP4) inhibition on responses to these peptides.
Phase:
Phase 4
Details
Lead Sponsor:
Vanderbilt University Medical Center
Treatments:
Bradykinin Kininogens LCZ 696 Neurokinin A Sacubitril and valsartan sodium hydrate drug combination Sitagliptin Phosphate Substance P Valsartan